2
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
2
Status
Withdrawn
1
Completed
1
Sponsor Class
OTHER
1
INDUSTRY
1
Study Type
Interventional
2
Sponsor
Cancer Type
Gastrointestinal
9
Genitourinary
3
Tumor-Agnostic
2
Thoracic
2
Gynecologic
2
Head & Neck
1
Breast
1
Conditions
Uterine Cervical Neoplasms
2
Triple Negative Breast Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Ovarian Neoplasms
1
Endometrial Neoplasms
1
Cholangiocarcinoma
1
Carcinoma, Ovarian Epithelial
1
Adenocarcinoma of Lung
1
Interventions
Paclitaxel
581
Carboplatin
528
Cisplatin
359
Bevacizumab
256
pembrolizumab
228
Gemcitabine
157
liposomal doxorubicin
132
Topotecan
131
olaparib
129
Cyclophosphamide
128
Radiotherapy
118
Taxes
114
Docetaxel
95
Brachytherapy
94
Drug Therapy
91
niraparib
88
Doxorubicin
86
Surveys and Questionnaires
85
Magnetic Resonance Spectroscopy
80
Blood Specimen Collection
74
Nivolumab
71
Specimen Handling
70
Hyperthermic Intraperitoneal Chemotherapy
64
Biopsy
63
fludarabine
57
Filgrastim
53
Letrozole
50
Oxaliplatin
49
durvalumab
47
Immunoglobulin G
47
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
bemarituzumab
×
Gynecologic
×
Clear all
NCT07146919
2026-04-23
ANGELICA
Centre Leon Berard
Phase 1/2
Withdrawn
NCT05325866
2026-02-04
FORTITUDE-301
Amgen
Phase 1/2
Completed
260 enrolled